Biomarkers for rheumatoid and psoriatic arthritis

Clinical Immunology

Volumn 161, Issue 1, 2015, Pages 2-10

  Verheul, M K ^a   Fearon, U ^b   Trouw, L A ^a   Veale, D J ^b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Autoantibodies; Biomarkers; Psoriatic arthritis; Rheumatoid arthritis; Serological biomarkers; Synovial tissue biomarkers

Indexed keywords

AUTOANTIBODY; B RAF KINASE; BIOLOGICAL MARKER; CARBAMYLATED PROTEIN ANTIBODY; INTERFERON; MALONALDEHYDE; MALONALDEHYDE ANTIBODY; MALONDIALDEHYDE ACETALDEHYDE ANTIBODY; PROTEIN 14 3 3; PROTEIN ANTIBODY; PROTEIN ARGININE DEIMINASE; PROTEIN ARGININE DEIMINASE 4; RA 33; RHEUMATOID FACTOR; UNCLASSIFIED DRUG; CITRULLINE;

ARTICLE; CARBAMOYLATION; CELL INFILTRATION; EARLY DIAGNOSIS; HUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGNOSIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SYNOVIUM; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; BLOOD; IMMUNOLOGY; SENSITIVITY AND SPECIFICITY;

ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOMARKERS; CITRULLINE; EARLY DIAGNOSIS; HUMANS; PROGNOSIS; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY;

EID: 84949627678     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2015.04.005     Document Type: Article

References (80)

1. van Nies J.A., Tsonaka R., Gaujoux-Viala C., Fautrel B., van der Helm-van Mil A.H. Evaluating relationships between symptom duration and persistence of rheumatoid arthritis: does a window of opportunity exist? Results on the Leiden Early Arthritis Clinic and ESPOIR cohorts. Ann. Rheum. Dis. 2015, 74(5):806-812.
2. Kirkham B., de Vlam K., Li W., Boggs R., Mallbris L., Nab H.W., Tarallo M. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial. Clin. Exp. Rheumatol. 2015, 33:11-19.
3. Scott D.L., Wolfe F., Huizinga T.W. Rheumatoid arthritis. Lancet 2010, 376:1094-1108.
4. Nestle F.O., Kaplan D.H., Barker J. Psoriasis. N. Engl. J. Med. 2009, 361:496-509.
5. Veale D.J. Psoriatic arthritis: recent progress in pathophysiology and drug development. Arthritis Res. Ther. 2013, 15:224.
6. Tobin A.M., Veale D.J., Fitzgerald O., Rogers S., Collins P., O'Shea D., Kirby B. Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J. Rheumatol. 2010, 37:1386-1394.
7. Gossec L., Smolen J.S., Gaujoux-Viala C., Ash Z., Marzo-Ortega H., van der Heijde D., FitzGerald O., Aletaha D., Balint P., Boumpas D., Braun J., Breedveld F.C., Burmester G., Canete J.D., de Wit M., Dagfinrud H., de Vlam K., Dougados M., Helliwell P., Kavanaugh A., Kvien T.K., Landewe R., Luger T., Maccarone M., McGonagle D., McHugh N., McInnes I.B., Ritchlin C., Sieper J., Tak P.P., Valesini G., Vencovsky J., Winthrop K.L., Zink A., Emery P. R. European League Against, European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann. Rheum. Dis. 2012, 71:4-12.
8. Smolen J.S., Landewe R., Breedveld F.C., Buch M., Burmester G., Dougados M., Emery P., Gaujoux-Viala C., Gossec L., Nam J., Ramiro S., Winthrop K., de Wit M., Aletaha D., Betteridge N., Bijlsma J.W., Boers M., Buttgereit F., Combe B., Cutolo M., Damjanov N., Hazes J.M., Kouloumas M., Kvien T.K., Mariette X., Pavelka K., van Riel P.L., Rubbert-Roth A., Scholte-Voshaar M., Scott D.L., Sokka-Isler T., Wong J.B., van der Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann. Rheum. Dis. 2014, 73:492-509.
9. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., Birnbaum N.S., Burmester G.R., Bykerk V.P., Cohen M.D., Combe B., Costenbader K.H., Dougados M., Emery P., Ferraccioli G., Hazes J.M., Hobbs K., Huizinga T.W., Kavanaugh A., Kay J., Kvien T.K., Laing T., Mease P., Menard H.A., Moreland L.W., Naden R.L., Pincus T., Smolen J.S., Stanislawska-Biernat E., Symmons D., Tak P.P., Upchurch K.S., Vencovsky J., Wolfe F., Hawker G. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann. Rheum. Dis. 2010, 69:1580-1588.
10. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H., Group C.S. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006, 54:2665-2673.
11. Inanc N., Dalkilic E., Kamali S., Kasapoglu-Gunal E., Elbir Y., Direskeneli H., Inanc M. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin. Rheumatol. 2007, 26:17-23.
12. Payet J., Goulvestre C., Biale L., Avouac J., Wipff J., Job-Deslandre C., Batteux F., Dougados M., Kahan A., Allanore Y. Anticyclic citrullinated peptide antibodies in rheumatoid and nonrheumatoid rheumatic disorders: experience with 1162 patients. J. Rheumatol. 2014, 41:2395-2402.
13. Dolcino M., Lunardi C., Ottria A., Tinazzi E., Patuzzo G., Puccetti A. Crossreactive autoantibodies directed against cutaneous and joint antigens are present in psoriatic arthritis. PLoS ONE 2014, 9:e115424.
14. Waaler E. On the occurrence of a factor in human serum activating the specific agglutintion of sheep blood corpuscles. 1939. Acta Pathol. Microbiol. Immunol. Scand. 2007, 115:422-438. (discussion 439).
15. Nishimura K., Sugiyama D., Kogata Y., Tsuji G., Nakazawa T., Kawano S., Saigo K., Morinobu A., Koshiba M., Kuntz K.M., Kamae I., Kumagai S. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann. Intern. Med. 2007, 146:797-808.
16. Vander Cruyssen B., Peene I., Cantaert T., Hoffman I.E., De Rycke L., Veys E.M., De Keyser F. Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmun. Rev. 2005, 4:468-474.
17. van Venrooij W.J., van Beers J.J., Pruijn G.J. Anti-CCP antibodies: the past, the present and the future. Nat. Rev. Rheumatol. 2011, 7:391-398.
18. Kroot E.J., de Jong B.A., van Leeuwen M.A., Swinkels H., van den Hoogen F.H., van't Hof M., van de Putte L.B., van Rijswijk M.H., van Venrooij W.J., van Riel P.L. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum. 2000, 43:1831-1835.
19. van der Helm-van Mil A.H., Verpoort K.N., Breedveld F.C., Toes R.E., Huizinga T.W. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res. Ther. 2005, 7:R949-R958.
20. Visser K., Verpoort K.N., van Dongen H., van der Kooij S.M., Allaart C.F., Toes R.E., Huizinga T.W., van der Helm-van Mil A.H. Pretreatment serum levels of anti-cyclic citrullinated peptide antibodies are associated with the response to methotrexate in recent-onset arthritis. Ann. Rheum. Dis. 2008, 67:1194-1195.
21. Verpoort K.N., Cheung K., Ioan-Facsinay A., van der Helm-van Mil A.H., de Vries-Bouwstra J.K., Allaart C.F., Drijfhout J.W., de Vries R.R., Breedveld F.C., Huizinga T.W., Pruijn G.J., Toes R.E. Fine specificity of the anti-citrullinated protein antibody response is influenced by the shared epitope alleles. Arthritis Rheum. 2007, 56:3949-3952.
22. Willemze A., Bohringer S., Knevel R., Levarht E.W., Stoeken-Rijsbergen G., Houwing-Duistermaat J.J., van der Helm-van Mil A.H., Huizinga T.W., Toes R.E., Trouw L.A. The ACPA recognition profile and subgrouping of ACPA-positive RA patients. Ann. Rheum. Dis. 2012, 71:268-274.
23. Scherer H.U., van der Woude D., Willemze A., Trouw L.A., Knevel R., Syversen S.W., van der Linden M.P., Lie B., Huizinga T.W., van der Heijde D.M., van der Helm-van Mil A.H., Kvien T.K., Toes R.E. Distinct ACPA fine specificities, formed under the influence of HLA shared epitope alleles, have no effect on radiographic joint damage in rheumatoid arthritis. Ann. Rheum. Dis. 2011, 70:1461-1464.
24. van Beers J.J., Willemze A., Jansen J.J., Engbers G.H., Salden M., Raats J., Drijfhout J.W., van der Helm-van Mil A.H., Toes R.E., Pruijn G.J. ACPA fine-specificity profiles in early rheumatoid arthritis patients do not correlate with clinical features at baseline or with disease progression. Arthritis Res. Ther. 2013, 15:R140.
25. Hansson M., Mathsson L., Schlederer T., Israelsson L., Matsson P., Nogueira L., Jakobsson P.J., Lundberg K., Malmstrom V., Serre G., Holmdahl R., Nystrand M., Klareskog L., Ronnelid J. Validation of a multiplex chip-based assay for the detection of autoantibodies against citrullinated peptides. Arthritis Res. Ther. 2012, 14:R201.
26. Ioan-Facsinay A., Willemze A., Robinson D.B., Peschken C.A., Markland J., van der Woude D., Elias B., Menard H.A., Newkirk M., Fritzler M.J., Toes R.E., Huizinga T.W., El-Gabalawy H.S. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum. 2008, 58:3000-3008.
27. van der Woude D., Rantapaa-Dahlqvist S., Ioan-Facsinay A., Onnekink C., Schwarte C.M., Verpoort K.N., Drijfhout J.W., Huizinga T.W., Toes R.E., Pruijn G.J. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann. Rheum. Dis. 2010, 69:1554-1561.
28. Ajeganova S., Andersson M.L., Frostegard J., Hafstrom I. Disease factors in early rheumatoid arthritis are associated with differential risks for cardiovascular events and mortality depending on age at onset: a 10-year observational cohort study. J. Rheumatol. 2013, 40:1958-1966.
29. Humphreys J.H., van Nies J.A., Chipping J., Marshall T., van der Helm-van Mil A.H., Symmons D.P., Verstappen S.M. Rheumatoid factor and anti-citrullinated protein antibody positivity, but not level, are associated with increased mortality in patients with rheumatoid arthritis: results from two large independent cohorts. Arthritis Res. Ther. 2014, 16:483.
30. Shi J., Knevel R., Suwannalai P., van der Linden M.P., Janssen G.M., van Veelen P.A., Levarht N.E., van der Helm-van Mil A.H., Cerami A., Huizinga T.W., Toes R.E., Trouw L.A. Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:17372-17377.
31. Jiang X., Trouw L.A., van Wesemael T.J., Shi J., Bengtsson C., Kallberg H., Malmstrom V., Israelsson L., Hreggvidsdottir H., Verduijn W., Klareskog L., Alfredsson L., Huizinga T.W., Toes R.E., Lundberg K., van der Woude D. Anti-CarP antibodies in two large cohorts of patients with rheumatoid arthritis and their relationship to genetic risk factors, cigarette smoking and other autoantibodies. Ann. Rheum. Dis. 2014, 73:1761-1768.
32. Shi J., van de Stadt L.A., Levarht E.W., Huizinga T.W., Hamann D., van Schaardenburg D., Toes R.E., Trouw L.A. Anti-carbamylated protein (anti-CarP) antibodies precede the onset of rheumatoid arthritis. Ann. Rheum. Dis. 2014, 73:780-783.
33. Gan R.W., Trouw L.A., Shi J., Toes R.E., Huizinga T.W., Demoruelle M.K., Kolfenbach J.R., Zerbe G.O., Deane K.D., Edison J.D., Gilliland W.R., Norris J.M., Holers V.M. Anti-carbamylated protein antibodies are present prior to rheumatoid arthritis and are associated with its future diagnosis. J. Rheumatol. 2015, 42(4):572-579.
34. Brink M., Verheul M.K., Rönnelid J., Berglin E., Holmdahl R., Toes R.E., Klareskog L., Trouw L.A., Rantapää-Dahlqvist S. Anti-carbamylated protein antibodies in the pre-symptomatic phase of rheumatoid arthritis, their relationship with multiple anti-citrulline peptide antibodies and association with radiological damage. Arthritis Res. Ther. 2015, 17.
35. Shi J., van de Stadt L.A., Levarht E.W., Huizinga T.W., Toes R.E., Trouw L.A., van Schaardenburg D. Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis. Arthritis Rheum. 2013, 65:911-915.
36. Yee A., Webb T., Seaman A., Infantino M., Meacci F., Manfredi M., Benucci M., Lakos G., Favalli E., Shioppo T., Meroni P.L., Mahler M. Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. Immunol. Res. 2015, 61:24-30.
37. Cvetkovic J.T., Wallberg-Jonsson S., Ahmed E., Rantapaa-Dahlqvist S., Lefvert A.K. Increased levels of autoantibodies against copper-oxidized low density lipoprotein, malondialdehyde-modified low density lipoprotein and cardiolipin in patients with rheumatoid arthritis. Rheumatology 2002, 41:988-995.
38. Thiele G.M., Duryee M.J., Anderson D.R., Klassen L.W., Mohring S.M., Young K.A., Benissan-Messan D., Sayles H., Dusad A., Hunter C.D., Sokolove J., Robinson W.H., O'Dell J.R., Nicholas A.P., Tuma D.J., Mikuls T.R. Malondialdehyde-acetaldehyde adducts and anti-malondialdehyde-acetaldehyde antibodies in rheumatoid arthritis. Arthritis Rheumatol. 2015, 67:645-655.
39. Vehkala L., Ukkola O., Kesaniemi Y.A., Kahonen M., Nieminen M.S., Salomaa V., Jula A., Horkko S. Plasma IgA antibody levels to malondialdehyde acetaldehyde-adducts are associated with inflammatory mediators, obesity and type 2 diabetes. Ann. Med. 2013, 45:501-510.
40. Rolla R., Vay D., Mottaran E., Parodi M., Traverso N., Arico S., Sartori M., Bellomo G., Klassen L.W., Thiele G.M., Tuma D.J., Albano E. Detection of circulating antibodies against malondialdehyde-acetaldehyde adducts in patients with alcohol-induced liver disease. Hepatology 2000, 31:878-884.
41. Zhao J., Zhao Y., He J., Jia R., Li Z. Prevalence and significance of anti-peptidylarginine deiminase 4 antibodies in rheumatoid arthritis. J. Rheumatol. 2008, 35:969-974.
42. Halvorsen E.H., Pollmann S., Gilboe I.M., van der Heijde D., Landewe R., Odegard S., Kvien T.K., Molberg O. Serum IgG antibodies to peptidylarginine deiminase 4 in rheumatoid arthritis and associations with disease severity. Ann. Rheum. Dis. 2008, 67:414-417.
43. Auger I., Balandraud N., Rak J., Lambert N., Martin M., Roudier J. New autoantigens in rheumatoid arthritis (RA): screening 8268 protein arrays with sera from patients with RA. Ann. Rheum. Dis. 2009, 68:591-594.
44. Darrah E., Giles J.T., Ols M.L., Bull H.G., Andrade F., Rosen A. Erosive rheumatoid arthritis is associated with antibodies that activate PAD4 by increasing calcium sensitivity. Sci. Transl. Med. 2013, 5:186ra165.
45. Li W., Wang W., Sun S., Sun Y., Pan Y., Wang L., Zhang R., Zhang K., Li J. Autoantibodies against the catalytic domain of BRAF are not specific serum markers for rheumatoid arthritis. PLoS ONE 2011, 6:e28975.
46. Nell V.P., Machold K.P., Stamm T.A., Eberl G., Heinzl H., Uffmann M., Smolen J.S., Steiner G. Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis. Ann. Rheum. Dis. 2005, 64:1731-1736.
47. Meyer O., Tauxe F., Fabregas D., Gabay C., Goycochea M., Haim T., Elias A., Kahn M.F. Anti-RA 33 antinuclear autoantibody in rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratin and antiperinuclear antibodies. Clin. Exp. Rheumatol. 1993, 11:473-478.
48. Sharma S., Ghosh S., Singh L.K., Sarkar A., Malhotra R., Garg O.P., Singh Y., Sharma R.S., Bhakuni D.S., Das T.K., Biswas S. Identification of autoantibodies against transthyretin for the screening and diagnosis of rheumatoid arthritis. PLoS ONE 2014, 9:e93905.
49. Guo Y., Wu Q., Ni B., Mou Z., Jiang Q., Cao Y., Dong H., Wu Y. Tryptase is a candidate autoantigen in rheumatoid arthritis. Immunology 2014, 142:67-77.
50. Ryu H.J., Takeuchi F., Kuwata S., Kim Y.J., Lee E.Y., Lee E.B., Song Y.W. The diagnostic utilities of anti-agalactosyl IgG antibodies, anti-cyclic citrullinated peptide antibodies, and rheumatoid factors in rheumatoid arthritis. Rheumatol. Int. 2011, 31:315-319.
51. Somers K., Geusens P., Elewaut D., De Keyser F., Rummens J.L., Coenen M., Blom M., Stinissen P., Somers V. Novel autoantibody markers for early and seronegative rheumatoid arthritis. J. Autoimmun. 2011, 36:33-46.
52. van der Pouw Kraan T.C., Wijbrandts C.A., van Baarsen L.G., Voskuyl A.E., Rustenburg F., Baggen J.M., Ibrahim S.M., Fero M., Dijkmans B.A., Tak P.P., Verweij C.L. Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients. Ann. Rheum. Dis. 2007, 66:1008-1014.
53. Raterman H.G., Vosslamber S., de Ridder S., Nurmohamed M.T., Lems W.F., Boers M., van de Wiel M., Dijkmans B.A., Verweij C.L., Voskuyl A.E. The interferon type I signature towards prediction of non-response to rituximab in rheumatoid arthritis patients. Arthritis Res. Ther. 2012, 14:R95.
54. Maksymowych W.P., Naides S.J., Bykerk V., Siminovitch K.A., van Schaardenburg D., Boers M., Landewe R., van der Heijde D., Tak P.P., Genovese M.C., Weinblatt M.E., Keystone E.C., Zhukov O.S., Abolhosn R.W., Popov J.M., Britsemmer K., van Kuijk A.W., Marotta A. Serum 14-3-3eta is a novel marker that complements current serological measurements to enhance detection of patients with rheumatoid arthritis. J. Rheumatol. 2014, 41:2104-2113.
55. Maksymowych W.P., van der Heijde D., Allaart C.F., Landewe R., Boire G., Tak P.P., Gui Y., Ghahary A., Kilani R., Marotta A. 14-3-3eta is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damage. Arthritis Res. Ther. 2014, 16:R99.
56. Eastman P.S., Manning W.C., Qureshi F., Haney D., Cavet G., Alexander C., Hesterberg L.K. Characterization of a multiplex, 12-biomarker test for rheumatoid arthritis. J. Pharm. Biomed. Anal. 2012, 70:415-424.
57. Hirata S., Dirven L., Shen Y., Centola M., Cavet G., Lems W.F., Tanaka Y., Huizinga T.W., Allaart C.F. A multi-biomarker score measures rheumatoid arthritis disease activity in the BeSt study. Rheumatology 2013, 52:1202-1207.
58. Markusse I.M., Dirven L., van den Broek M., Bijkerk C., Han K.H., Ronday H.K., Bolce R., Sasso E.H., Kerstens P.J., Lems W.F., Huizinga T.W., Allaart C.F. A multibiomarker disease activity score for rheumatoid arthritis predicts radiographic joint damage in the BeSt study. J. Rheumatol. 2014, 41:2114-2119.
59. Cheng Y., Chen Y., Sun X., Li Y., Huang C., Deng H., Li Z. Identification of potential serum biomarkers for rheumatoid arthritis by high-resolution quantitative proteomic analysis. Inflammation 2014, 37:1459-1467.
60. Ammitzboll C.G., Thiel S., Jensenius J.C., Ellingsen T., Horslev-Petersen K., Hetland M.L., Junker P., Krogh N.S., Ostergaard M., Stengaard-Pedersen K. M-ficolin levels reflect disease activity and predict remission in early rheumatoid arthritis. Arthritis Rheum. 2013, 65:3045-3050.
61. van Kuijk A.W., Tak P.P. Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy. Curr. Rheumatol. Rep. 2011, 13:353-359.
62. Veale D., Yanni G., Rogers S., Barnes L., Bresnihan B., Fitzgerald O. Reduced synovial membrane macrophage numbers, ELAM-1 expression, and lining layer hyperplasia in psoriatic arthritis as compared with rheumatoid arthritis. Arthritis Rheum. 1993, 36:893-900.
63. Reece R.J., Canete J.D., Parsons W.J., Emery P., Veale D.J. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum. 1999, 42:1481-1484.
64. Fearon U., Reece R., Smith J., Emery P., Veale D.J. Synovial cytokine and growth factor regulation of MMPs/TIMPs: implications for erosions and angiogenesis in early rheumatoid and psoriatic arthritis patients. Ann. N. Y. Acad. Sci. 1999, 878:619-621.
65. Haringman J.J., Gerlag D.M., Zwinderman A.H., Smeets T.J., Kraan M.C., Baeten D., McInnes I.B., Bresnihan B., Tak P.P. Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann. Rheum. Dis. 2005, 64:834-838.
66. Bresnihan B., Pontifex E., Thurlings R.M., Vinkenoog M., El-Gabalawy H., Fearon U., Fitzgerald O., Gerlag D.M., Rooney T., van de Sande M.G., Veale D., Vos K., Tak P.P. Synovial tissue sublining CD68 expression is a biomarker of therapeutic response in rheumatoid arthritis clinical trials: consistency across centers. J. Rheumatol. 2009, 36:1800-1802.
67. van de Sande M.G., Gerlag D.M., Lodde B.M., van Baarsen L.G., Alivernini S., Codullo V., Felea I., Vieira-Sousa E., Fearon U., Reece R., Montecucco C., Veale D.J., Pitzalis C., Emery P., Klareskog L., McInnes I.B., Tak P.P. Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trials. Ann. Rheum. Dis. 2011, 70:423-427.
68. Walsh C.A., Fearon U., FitzGerald O., Veale D.J., Bresnihan B. Decreased CD20 expression in rheumatoid arthritis synovium following 8weeks of rituximab therapy. Clin. Exp. Rheumatol. 2008, 26:656-658.
69. Pontifex E.K., Gerlag D.M., Gogarty M., Vinkenoog M., Gibbs A., Burgman I., Fearon U., Bresnihan B., Tak P.P., Gibney R.G., Veale D.J., FitzGerald O. Change in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy-a single centre, open-label study. Arthritis Res. Ther. 2011, 13:R7.
70. de Hair M.J., van de Sande M.G., Ramwadhdoebe T.H., Hansson M., Landewe R., van der Leij C., Maas M., Serre G., van Schaardenburg D., Klareskog L., Gerlag D.M., van Baarsen L.G., Tak P.P. Features of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritis. Arthritis Rheumatol. 2014, 66:513-522.
71. de Hair M.J., Harty L.C., Gerlag D.M., Pitzalis C., Veale D.J., Tak P.P. Synovial tissue analysis for the discovery of diagnostic and prognostic biomarkers in patients with early arthritis. J. Rheumatol. 2011, 38:2068-2072.
72. Villanova F., Di Meglio P., Nestle F.O. Biomarkers in psoriasis and psoriatic arthritis. Ann. Rheum. Dis. 2013, 72(Suppl. 2):ii104-ii110.
73. Kane D., Jensen L.E., Grehan S., Whitehead A.S., Bresnihan B., Fitzgerald O. Quantitation of metalloproteinase gene expression in rheumatoid and psoriatic arthritis synovial tissue distal and proximal to the cartilage-pannus junction. J. Rheumatol. 2004, 31:1274-1280.
74. Green M.J., Gough A.K., Devlin J., Smith J., Astin P., Taylor D., Emery P. Serum MMP-3 and MMP-1 and progression of joint damage in early rheumatoid arthritis. Rheumatology 2003, 42:83-88.
75. Verstappen S.M., Poole A.R., Ionescu M., King L.E., Abrahamowicz M., Hofman D.M., Bijlsma J.W., Lafeber F.P., g.Utrecht Rheumatoid Arthritis Cohort Study Radiographic joint damage in rheumatoid arthritis is associated with differences in cartilage turnover and can be predicted by serum biomarkers: an evaluation from 1 to 4years after diagnosis. Arthritis Res. Ther. 2006, 8:R31.
76. Chandran V., Shen H., Pollock R.A., Pellett F.J., Carty A., Cook R.J., Gladman D.D. Soluble biomarkers associated with response to treatment with tumor necrosis factor inhibitors in psoriatic arthritis. J. Rheumatol. 2013, 40:866-871.
77. Mullan R.H., Matthews C., Bresnihan B., FitzGerald O., King L., Poole A.R., Fearon U., Veale D.J. Early changes in serum type II collagen biomarkers predict radiographic progression at one year in inflammatory arthritis patients after biologic therapy. Arthritis Rheum. 2007, 56:2919-2928.
78. Fitzgerald O., Chandran V. Update on biomarkers in psoriatic arthritis: a report from the GRAPPA 2010 annual meeting. J. Rheumatol. 2012, 39:427-430.
79. Dalbeth N., Pool B., Smith T., Callon K.E., Lobo M., Taylor W.J., Jones P.B., Cornish J., McQueen F.M. Circulating mediators of bone remodeling in psoriatic arthritis: implications for disordered osteoclastogenesis and bone erosion. Arthritis Res. Ther. 2010, 12:R164.
80. Yarwood A., Huizinga T.W., Worthington J. The genetics of rheumatoid arthritis: risk and protection in different stages of the evolution of RA. Rheumatology 2014, Sep 18. pii: keu323. [Epub ahead of print] Review.